Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

Inclusion Criteria:

• Capable of giving signed informed consent which includes compliance with therequirements and restrictions listed in the informed consent form (ICF) and in thisprotocol.

• Having been enrolled and is still receiving treatment with tafasitamab at the end ofa parent tafasitamab clinical study.

• Is tolerating tafasitamab treatment at the dose specified in the parent protocol asassessed by the Investigator.

• Is in complete/partial response or stable disease and is receiving clinical benefitfrom treatment with tafasitamab in the parent study, as assessed by theInvestigator.

• Has demonstrated compliance, as assessed by the Investigator, with the parentprotocol requirements.

• Willingness and ability to comply with scheduled visits, treatment plans, and anyother study procedures indicated in this protocol.

Exclusion Criteria:

• Patient who is legally institutionalized, or under judicial protection.

• Has met one or more criteria for permanent tafasitamab treatment discontinuation asstipulated in the parent protocol.

• Able to access tafasitamab outside a clinical study.

• Patient with an uncontrolled intercurrent illness or any concurrent condition that,in the Investigator's opinion, would jeopardize the safety of the patient orcompliance with the protocol.

• A female patient who is pregnant confirmed by a pregnancy test prior to enrollment,breastfeeding, or a woman of childbearing potential (WOCBP) who does not agree tofollow the contraceptive guidance during the treatment period and for at least 3months after the last dose of study treatment, and does not refrain from donatingoocytes during this period.

• A male patient who does not agree to use contraception as detailed in thecontraceptive guidance during the treatment period and for at least 3 months afterthe last dose of study treatment (if they have a heterosexual partner who is a womanof childbearing potential) and who does not refrain from donating sperm during thisperiod.